Sep. 9 at 7:21 PM
$CHRS The biggest news from the conference to me was the "good confidence" on the earnout payments. An additional 72M will be big. I was hopeful this would be the case, but it was nice to hear him say it. We also got confirmation on my belief that they will sell the rights to their future drugs outside of the U.S. to fund development. He suggested such a deal would include a payment upfront. The strategy to me seems to be clear: See this through without selling the company, focus on the United States and be willing to give up rights elsewhere for the chance to see their vision through. Of course, I am still sure they will listen to outright buyout offers ... but I think their intent is to handle it as outlined above without taking out loans or diluting the stock.
